NCT04611373

Clinical Study on the Efficacy of Acetazolamide Combined With Levamisole in the Treatment of HCC

A Single-center, Single-arm, Open, Prospective, and Exploratory Clinical Study on the Efficacy of Acetazolamide Combined With Levamisole in the Treatment of Advanced HCC

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: The First Affiliated Hospital of Zhengzhou University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of acetazolamide combined with levamisole in the treatment of advanced HCC.

Detailed description

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer-related deaths in the world. Because HCC is insidious and early diagnosis is difficult, most patients have locally advanced or distant metastasis at the time of diagnosis. So they are not suitable candidates for curative treatments by resection or transplantation. Currently, There are only not more than five drugs to be selected for advanced HCC, although it prolongs the survival for less than 3 months. Recently, metabolomics studies of HCC have shown that typical Warburg effect was observed in hepatoma carcinoma cells. Arginine hydrochloride is a new anticancer drug in the treatment of HCC, which is mainly aimed at the pathway of energy metabolism.acetazolamide may play an anti-tumor role by inhibiting the reverse TCA cycle. The investigators have been proceeding this trial to evaluate the efficacy and safety of acetazolamide combined with levamisole in the treatment of advanced HCC.

Conditions

• HCC

Interventions

Type	Name	Description
DRUG	Acetazolamide Levamisole	Acetazolamide tablet 25mg/ tablet, 2 tablets a day Levamisole 25mg/ tablet, 6 tablets/day Continue treatment until the disease progresses

Timeline

• Start date: 2020-05-01
• Primary completion: 2020-12-01
• Completion: 2021-05-31
• First posted: 2020-11-02
• Last updated: 2020-11-02

Locations

1 site across 1 country: China